Tellgen

Tellgen Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Tellgen (300642.SZ) as of Oct 30, 2026 is 3,992.10 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 476.69 % — a change of 737.47% (higher).

Cash Conversion

3,992.10 %

YoY

737.47%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Tellgen is 2025 3,992.10 % . Cash Conversion Rate (OCF/Net Income) of Tellgen was 2024 476.69 % . It decreases by 737.47% higher compared to the previous year.

The Tellgen Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
113.85 CNY
Jan 1, 2019
111.35 CNY
Jan 1, 2020
80.32 CNY
Jan 1, 2021
51.29 CNY
Jan 1, 2022
132.03 CNY
Jan 1, 2023
141.38 CNY
Jan 1, 2024
476.69 CNY
Jan 1, 2025
3,992.10 CNY
The Tellgen Cash Conversion history
YEARCash ConversionYoY
3,992.10 %+737.47%
476.69 %+237.16%
141.38 %+7.08%
132.03 %+157.44%
51.29 %-36.15%
80.32 %-27.86%
111.35 %-2.20%
113.85 %+36.21%
83.58 %-16.97%
100.67 %+2.40%
98.31 %-13.27%
113.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Cash Conversion Rate (OCF/Net Income) of Tellgen is 3,992.10 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Tellgen changed from 476.69 % to 3,992.10 %, representing a 737.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Tellgen since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Tellgen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tellgen

All Key Metrics — Tellgen